Contact
searchSearch
HMP Global

Non-Small Cell Lung Cancer Topic Center

Interactive Features
Poll Quiz

news


News
Stage and Access Predict Outcomes in Early Onset NSCLC
11/10/2025
Juliet Gallagher
Early-onset non–small cell lung cancer (NSCLC) remains understudied. A retrospective cohort analysis published in JAMA Network Open used SEER data (2010–2021) to evaluate which demographic, clinical, and socioeconomic factors are associated...
Early-onset non–small cell lung cancer (NSCLC) remains understudied. A retrospective cohort analysis published in JAMA Network Open used SEER data (2010–2021) to evaluate which demographic, clinical, and socioeconomic factors are associated...
Early-onset non–small cell lung...
11/10/2025
First Report Managed Care
News
Medicaid Expansion Linked to Improved Access to Local Therapy for Early-Stage Lung Cancer
06/09/2025
Juliet Gallagher
A recent retrospective study using the National Cancer Database suggests that Medicaid expansion under the Affordable Care Act (ACA) may improve access to local therapy—surgery or stereotactic body radiation therapy (SBRT)—for patients with...
A recent retrospective study using the National Cancer Database suggests that Medicaid expansion under the Affordable Care Act (ACA) may improve access to local therapy—surgery or stereotactic body radiation therapy (SBRT)—for patients with...
A recent retrospective study...
06/09/2025
First Report Managed Care
News
Immune Checkpoint Inhibitor Regimens Drive Higher Costs in First-Line NSCLC Treatment
05/13/2025
Lisa Kuhns, PhD, MD
First-line (1L) treatment with immune checkpoint inhibitors (ICIs), particularly in combination with chemotherapy, is the most frequently used and costliest systemic therapy for metastatic non-small cell lung cancer (NSCLC) patients without...
First-line (1L) treatment with immune checkpoint inhibitors (ICIs), particularly in combination with chemotherapy, is the most frequently used and costliest systemic therapy for metastatic non-small cell lung cancer (NSCLC) patients without...
First-line (1L) treatment with...
05/13/2025
First Report Managed Care
News
Continued Immunotherapy Beyond Progression May Extend Survival in Metastatic NSCLC
04/23/2025
Grace Taylor, MS, MA
Study finds extended survival with immunotherapy beyond disease progression for patients with non–small cell lung cancer.
Study finds extended survival with immunotherapy beyond disease progression for patients with non–small cell lung cancer.
Study finds extended survival...
04/23/2025
First Report Managed Care
News
Study Quantifies How Social and Structural Factors Drive Racial Inequities in NSCLC Care
04/11/2025
Lisa Kuhns, PhD, MD
Black patients with non-small cell lung cancer (NSCLC) in the US experience significantly worse care and outcomes compared with White patients, and these disparities are largely explained by exposure to structural racism across the health...
Black patients with non-small cell lung cancer (NSCLC) in the US experience significantly worse care and outcomes compared with White patients, and these disparities are largely explained by exposure to structural racism across the health...
Black patients with non-small...
04/11/2025
First Report Managed Care
News
Immune-Related Adverse Events With ICIs Linked to Improved Survival in Metastatic NSCLC
12/09/2024
Jolynn Tumolo
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically...
12/09/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
Hannah Musick
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
Amivantamab–Lazertinib Extends Progression-Free Survival in Untreated EGFR-Mutated NSCLC
10/11/2024
Jolynn Tumolo
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was...
10/11/2024
First Report Managed Care
News
Family History of Cancer Impacts Survival and Treatment Outcomes in Patients With NSCLC
10/11/2024
Lisa Kuhns, PhD, MD
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the...
10/11/2024
First Report Managed Care
News
Challenges and Emerging Strategies in Overcoming Resistance in EGFR-Mutant NSCLC
09/10/2024
Lisa Kuhns, PhD, MD
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results,...
09/10/2024
First Report Managed Care

Behind the Bill

Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care
BEHIND THE BILL
When Agencies Lose Power: How 3 Seismic Shifts are Transforming Pharmaceutical Regulation
05/07/2025
Katie Hayes, MJ
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months,...
05/07/2025
First Report Managed Care
Behind the Bill
The Medicare Paradox, Part 3: Strategic Trade Doesn’t Have to be a Zero-Sum Game
05/07/2025
Katie Hayes, MJ
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve...
05/07/2025
First Report Managed Care

Trending Articles

Advancements and Challenges in Diabetes Management
02/29/2024
02/29/2024
First Report Managed Care
News
LGBT Adults Face Higher Rates of Discrimination and Unfair Treatment in Health Care
04/05/2024
Hannah Musick
A Kaiser Family Foundation (KFF) report reveals the significant discrimination and unfair treatment faced by LGBT adults in the US, impacting mental health and access to health care, particularly for younger, lower-income, and women within...
A Kaiser Family Foundation (KFF) report reveals the significant discrimination and unfair treatment faced by LGBT adults in the US, impacting mental health and access to health care, particularly for younger, lower-income, and women within...
A Kaiser Family Foundation (KFF)...
04/05/2024
First Report Managed Care
News
Demodex Infestation Found in 9 of 10 Eye Clinic Patients Using 2-Minute Technique
05/09/2024
Jolynn Tumolo
Demodex mites were found in the eyelashes of 94% of patients examined with a simple diagnostic technique at a standard ophthalmic practice, according to a study published online in the journal Clinical Ophthalmology.
Demodex mites were found in the eyelashes of 94% of patients examined with a simple diagnostic technique at a standard ophthalmic practice, according to a study published online in the journal Clinical Ophthalmology.
Demodex mites were found in the...
05/09/2024
First Report Managed Care
Conference Coverage
Administrative Health Claims Data Study Highlights Demographics of Patients With Multiple Sclerosis in the US
05/31/2024
Grace Taylor, MS, MA
A new study highlights demographic data on subpopulations of people with multiple sclerosis (MS) in the US based on findings from administrative health claims (AHC) data sets.
A new study highlights demographic data on subpopulations of people with multiple sclerosis (MS) in the US based on findings from administrative health claims (AHC) data sets.
A new study highlights...
05/31/2024
First Report Managed Care
Blog
Why We’re Already Thinking Ahead to 2028 Part B Drug Price Negotiations
07/18/2024
Katie Hayes, MJ
Learn why industry stakeholders should prepare for 2028 negotiations now to ensure long-term financial stability and regulatory compliance.
Learn why industry stakeholders should prepare for 2028 negotiations now to ensure long-term financial stability and regulatory compliance.
Learn why industry stakeholders...
07/18/2024
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use